| Not Yet Recruiting | Study of NM8074 in Patients With Immunoglobulin A Nephropathy (IgAN) NCT06454110 | NovelMed Therapeutics | Phase 2 |
| Not Yet Recruiting | Study to Assess the Efficacy, Pharmacokinetics, Safety and Tolerability of Atrasentan in Pediatric Patients Wi NCT07498335 | Novartis Pharmaceuticals | Phase 3 |
| Not Yet Recruiting | IgA Nephropathy Insights From Treatment Experience Among Patients Receiving Iptacopan and/or Atrasentan Using NCT07481084 | Novartis Pharmaceuticals | — |
| Recruiting | Nefecon and Ambrisentan in IgA Nephropathy NCT07030894 | The First Hospital of Jilin University | Phase 4 |
| Not Yet Recruiting | Study of CM313 in Subject With IgA Nephropathy NCT06830395 | Keymed Biosciences Co.Ltd | Phase 2 |
| Recruiting | Study of BHV-1400 in IgA Nephropathy NCT07054684 | Biohaven Therapeutics Ltd. | Phase 1 |
| Completed | A Clinical Study to Evaluate the Effect of Food on the Pharmacokinetic Profiles of HRS-5965 Capsules in Health NCT07035665 | Chengdu Suncadia Medicine Co., Ltd. | Phase 1 |
| Not Yet Recruiting | Epithelial Dysmetabolism and Renal Fibrosis in ANCA Vasculitis NCT07010250 | Assistance Publique - Hôpitaux de Paris | — |
| Not Yet Recruiting | Therapeutic Effect of Hydroxychloroquine on Immunoglobulin A (IgA) Nephropathy Course QUIgAN Study NCT06350630 | Centre Hospitalier Universitaire de Saint Etienne | Phase 2 |
| Recruiting | Which of the Commonly Available and Approved Drugs in Addition to Standard of Care Can Significantly Improve t NCT06676384 | Christian Medical College, Vellore, India | Phase 4 |
| Not Yet Recruiting | A Clinical Study of SCTC21C in Participants With Plasma Cell-driven Autoimmune Diseases NCT06774664 | Sinocelltech Ltd. | Phase 1 / Phase 2 |
| Recruiting | Efficacy and Safety of Extended TARPEYO® Treatment Beyond 9 Months in Adult Patients With Primary IgA Nephropa NCT06712407 | Calliditas Therapeutics AB | Phase 4 |
| Not Yet Recruiting | IM19 CAR-T Cell Therapy for IgA Nephropathy Patients and Membranous Nephropathy Patients NCT06690359 | Beijing Immunochina Medical Science & Technology Co., Ltd. | EARLY_Phase 1 |
| Recruiting | Trial of the Impact of Sibeprenlimab on Immunoglobulin A Nephropathy Kidney Tissue NCT06740526 | Otsuka Pharmaceutical Development & Commercialization, Inc. | Phase 2 |
| Not Yet Recruiting | Effect of Finerenone in IgA Nephropathy NCT06580288 | Zhejiang University | Phase 3 |
| Not Yet Recruiting | The Effect of OSA on Severity and Prognosis of Patients With IgAN NCT06393036 | Peking University First Hospital | — |
| Withdrawn | A Phase 2 Study to Evaluate the Safety, PD, PK, and Clinical Activity of ADX-097 in Participants With IgAN, LN NCT06419205 | Q32 Bio Inc. | Phase 2 |
| Active Not Recruiting | Study of ARO-CFB in Adult Healthy Volunteers NCT06209177 | Arrowhead Pharmaceuticals | Phase 1 |
| Recruiting | A Study of Probiotics in IgA Nephropathy NCT06767592 | University of Leicester | N/A |
| Completed | Randomized, Double-blind, Placebo-controlled, Crossover Study of Atrasentan in Subjects With IgA Nephropathy NCT05834738 | Novartis Pharmaceuticals | Phase 2 |
| Active Not Recruiting | A Study of Zigakibart in Adults With IgA Nephropathy NCT05852938 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Atacicept in Subjects With IgA Nephropathy NCT04716231 | Vera Therapeutics, Inc. | Phase 3 |
| Recruiting | A First in Human Study to Evaluate Safety, Tolerability, Pharmacology of HS-10390 in Healthy Subjects NCT05942625 | Hansoh BioMedical R&D Company | Phase 1 |
| Active Not Recruiting | A Study to Evaluate the Efficacy and Safety of SC0062 in the Treatment of Chronic Kidney Disease NCT05687890 | Biocity Biopharmaceutics Co., Ltd. | Phase 2 |
| Recruiting | Clinical Study of CM338 in the Treatment of Immunoglobulin A Nephropathy NCT05775042 | Keymed Biosciences Co.Ltd | Phase 2 |
| Not Yet Recruiting | Study of Telitacicept in Patients With Refractory IgA Nephropathy NCT05596708 | Second Affiliated Hospital, School of Medicine, Zhejiang University | Phase 2 / Phase 3 |
| Recruiting | TESTING -ON Post-Trial ObservatioNal Cohort Study NCT05434325 | The George Institute | — |
| Completed | Study of the Clinical Efficacy and Safety of Finerenone for the Treatment of IGA Nephropathy NCT06460987 | The Fourth Affiliated Hospital of Zhejiang University School of Medicine | — |
| Unknown | Bortezomib for Treating Glomerular Diseases NCT05383547 | Ruijin Hospital | N/A |
| Completed | A Study to Evaluate the Safety, Tolerability and Pharmacokinetics Pharmacodynamics of SHR-2010 by Intravenousl NCT05398510 | Guangdong Hengrui Pharmaceutical Co., Ltd | Phase 1 |
| Unknown | Oxford Classification and Clinical Remission After Initial Treatments in Patients With IgA Nephropathy NCT05528991 | Shenzhen Second People's Hospital | — |
| Terminated | Safety and Efficacy of AT-1501 in Patients With IgA Nephropathy (IgAN) NCT05125068 | Eledon Pharmaceuticals | Phase 2 |
| Completed | Study of ARO-C3 in Adult Healthy Volunteers and Patients With Complement Mediated Renal Disease NCT05083364 | Arrowhead Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | A Clinical Research on the Use of Fecal Bacteria Transplantation for Treatment of IgA Nephropathy NCT05182775 | Shanxi Provincial People's Hospital | N/A |
| Terminated | A Study of Telitacicept for Injection (RC18) in Subjects With IgA Nephropathy NCT04905212 | RemeGen Co., Ltd. | Phase 2 |
| Completed | A Study to Evaluate the Efficacy and Safety of HR19042 Capsules in the Treatment of Primary IgA Nephropathy. NCT05016323 | Jiangsu HengRui Medicine Co., Ltd. | Phase 2 |
| Unknown | Steroids Therapy in IgA Nephropathy With Crescents NCT04833374 | Sixth Affiliated Hospital, Sun Yat-sen University | Phase 3 |
| Unknown | SodiUm Restriction by Behavioral Intervention NCT04805047 | First Affiliated Hospital Xi'an Jiaotong University | N/A |
| Active Not Recruiting | Atrasentan in Patients With Proteinuric Glomerular Diseases NCT04573920 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Study of Efficacy and Safety of LNP023 in Primary IgA Nephropathy Patients NCT04578834 | Novartis Pharmaceuticals | Phase 3 |
| Active Not Recruiting | Atrasentan in Patients With IgA Nephropathy NCT04573478 | Chinook Therapeutics, Inc. | Phase 3 |
| Recruiting | The Chinese Registry of Prognostic Study of IgA Nephropathy (CRPIGA) NCT04858724 | Ruijin Hospital | — |
| Unknown | The Applicaiton of Immune Repertoire in the Diagnosis and Disease Monitoring of IgA Nephropathy NCT04438603 | Xinhua Hospital, Shanghai Jiao Tong University School of Medicine | — |
| Completed | Rituximab and RASi in Patients with IgAN NCT04525729 | Nan Chen,MD | Phase 4 |
| Unknown | A Randomized, Controlled Clinical Study of Rituximab in Treatment of Primary IgA Nephropathy NCT05824390 | XIEJINGYUAN | Phase 4 |
| Recruiting | Correlation of Microbiome and Metabonomics With IgA Nephropathy NCT05190848 | Guangdong Provincial People's Hospital | — |
| Terminated | Study of Safety and Efficacy of AVB-S6-500 in Patients With IgA Nephropathy NCT04042623 | Aravive, Inc. | Phase 2 |
| Recruiting | KOrea Renal Biobank NEtwoRk System TOward NExt-generation Analysis NCT03929887 | Seoul National University Hospital | — |
| Active Not Recruiting | Safety and Tolerability of BION-1301 in Healthy Volunteers and Adults With IgA Nephropathy (IgAN) NCT03945318 | Novartis Pharmaceuticals | Phase 1 / Phase 2 |
| Completed | First in Human Study to Assess Safety of VIS649 in Healthy Subjects NCT03719443 | Visterra, Inc. | Phase 1 |
| Terminated | Study of the Safety and Efficacy of OMS721 in Patients With Immunoglobulin A (IgA) Nephropathy NCT03608033 | Omeros Corporation | Phase 3 |
| Completed | Phase II Study Assessing Safety and Efficacy of APL-2 in Glomerulopathies NCT03453619 | Apellis Pharmaceuticals, Inc. | Phase 2 |
| Completed | Treatment of IgA Nephropathy According to Renal Lesions NCT03188887 | Assistance Publique - Hôpitaux de Paris | Phase 3 |
| Completed | Study of Safety and Efficacy of LNP023 in Patients With Kidney Disease Caused by Inflammation NCT03373461 | Novartis Pharmaceuticals | Phase 2 |
| Completed | Longterm Renal Oucomes of STOP-IgAN Trial Participants NCT03488368 | RWTH Aachen University | — |
| Completed | A Phase 2 Trial of the Safety and Efficacy of Bardoxolone Methyl in Patients With Rare Chronic Kidney Diseases NCT03366337 | Biogen | Phase 2 |
| Unknown | Fecal Microbiota Transplantation for Refractory IgA Nephropathy NCT03633864 | Air Force Military Medical University, China | Phase 2 |
| Terminated | Efficacy and Safety of Atacicept in IgA Nephropathy NCT02808429 | EMD Serono Research & Development Institute, Inc. | Phase 2 |
| Unknown | Extended Follow-up of Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephro NCT03218852 | Guangdong Provincial People's Hospital | Phase 4 |
| Recruiting | IgA Nephropathy Biomarkers Evaluation Study (INTEREST) NCT02954419 | Sun Yat-sen University | — |
| Unknown | Efficacy and Safety of a Combination of Mycophenolate Mofetil and Corticosteroid in Advanced IgA Nephropathy NCT02981212 | Yonsei University | Phase 4 |
| Unknown | Validity and Security of Reh-acteoside Therapy for Patients of IgA Nephropathy NCT02662283 | Sun Yat-sen University | Phase 2 / Phase 3 |
| Unknown | Registry of IgA Nephropathy in Chinese Children NCT03015974 | Peking University First Hospital | — |
| Withdrawn | Open Label Study of Fostamatinib in the Treatment of IgA Nephropathy NCT02433236 | Rigel Pharmaceuticals | Phase 2 |
| Withdrawn | Acthar on Proteinuria in IgA Nephropathy Patients NCT02382523 | Baylor College of Medicine | Phase 4 |
| Withdrawn | BRILLIANT-SC: A Study of the Efficacy and Safety of Blisibimod Administration in Subjects With IgA Nephropathy NCT02052219 | Anthera Pharmaceuticals | Phase 3 |
| Completed | Safety and Efficacy Study of Fostamatinib to Treat Immunoglobin A (IgA) Nephropathy NCT02112838 | Rigel Pharmaceuticals | Phase 2 |
| Unknown | Efficacy and Safety of Abelmoschus Manihot for IgA Nephropathy NCT02231125 | Chen Xiangmei | Phase 4 |
| Unknown | Treatment of IgAN With Multi-glycoside of Tripterygium Wilfordii HOOK. f. NCT02187900 | Second Xiangya Hospital of Central South University | Phase 3 |
| Completed | The Effects of Mycophenolate Mofetil (MMF) on Renal Outcomes in Advanced Immunoglobulin A (IgA) Nephropathy Pa NCT01854814 | Fan Fan Hou | N/A |
| Completed | BRIGHT-SC: Blisibimod Response in IgA Nephropathy Following At-Home Treatment by Subcutaneous Administration NCT02062684 | Anthera Pharmaceuticals | Phase 2 / Phase 3 |
| Completed | The Correlation of Periostin and Renal Pathology in Chronic Kidney Disease Patients NCT02493101 | Chulalongkorn University | — |
| Completed | IgA Nephropathy, Lymphocyte Homing and IgA Class Switch NCT01775527 | University Hospital, Limoges | N/A |
| Unknown | Probiotics in IgA Nephropathy NCT01781312 | Uppsala University Hospital | N/A |
| Unknown | Treatment of Prednisone Plus Cyclophosphamide in Patients With Advanced-stage IgA Nephropathy NCT01758120 | Guangdong Provincial People's Hospital | Phase 4 |
| Recruiting | IgA Nephropathy Registration Initiative of High Quality (INSIGHT) NCT03001947 | Sun Yat-sen University | — |
| Completed | Multicenter Study Evaluating the Performance of the Assay of Anti-hinge Region Antibodies in the Diagnosis of NCT02526966 | Centre Hospitalier Universitaire de Saint Etienne | N/A |
| Completed | A Survey of Factors Affecting an Early or Delayed Diagnosis of IgA Nephropathy NCT01538433 | Guangdong Provincial People's Hospital | — |
| Completed | Biomarkers for the Progression of IgA Nephropathy NCT02529722 | Istanbul University | — |
| Completed | An Observational Study of IgA Nephropathy: Pathological Variants and Clinical Data NCT01502579 | Guangdong Provincial People's Hospital | — |
| Suspended | Effect of Tonsillectomy on Longterm Renal Outcome of IgA Nephropathy NCT02471599 | Sun Yat-sen University | N/A |
| Completed | The Effectiveness of Enough Steroids as Inducement Therapy in Minimal Change Disease-like IgA Nephropathy NCT01451710 | Nanjing University School of Medicine | N/A |
| Completed | Additive Renoprotective Effects of Oral Calcitriol in IgA Nephropathy Patients Taking Renin-Angiotensin System NCT01237028 | Yonsei University | N/A |
| Completed | A Study to Evaluate the Efficacy and Safety of Tacrolimus in Korean Nephropathy Patients NCT01224028 | Astellas Pharma Inc | Phase 2 |
| Unknown | Diet Intervention in Food Sensitive Patients With IgA Nephropathy NCT01203007 | Uppsala University Hospital | N/A |
| Completed | Pilot Study of Velcade® in IgA Nephropathy NCT01103778 | The Rogosin Institute | Phase 4 |
| Unknown | Study of Standardized Treatment of Integrative Medicine With the Severe IgA Nephropath NCT01879514 | Shanghai University of Traditional Chinese Medicine | N/A |
| Recruiting | National Registry of Rare Kidney Diseases NCT06065852 | UK Kidney Association | — |
| Terminated | Aldosterone Breakthrough During Diovan, Tekturna, and Combination Therapy in Patients With Proteinuric Kidney NCT01129557 | Columbia University | Phase 4 |
| Completed | Aliskiren for Proteinuric IgAN Despite Angiotensin Blockade NCT00922311 | The University of Hong Kong | Phase 4 |
| Completed | Aliskiren for Immunoglobulin A (IgA) Nephropathy NCT00870493 | Chinese University of Hong Kong | Phase 3 |
| Terminated | Prospective Study of TW in Treatment of IgAN With Asymptomatic Abnormal Urinalysis NCT00885547 | Nanjing University School of Medicine | N/A |
| Terminated | Safety Study of of Intravenous CCL2-LPM in Patients With IgA Nephropathy NCT00856674 | Osprey Pharmaceuticals USA, Inc. | Phase 1 |
| Completed | Rituximab in Progressive Immunoglobulin A (IgA) Nephropathy NCT00498368 | Mayo Clinic | Phase 4 |
| Completed | Supportive Versus Immunosuppressive Therapy for the Treatment Of Progressive IgA Nephropathy NCT00554502 | RWTH Aachen University | Phase 3 |
| Withdrawn | Paricalcitol for the Treatment of Immunoglobulin A Nephropathy NCT00599963 | Chinese University of Hong Kong | Phase 3 |
| Completed | Efficacy and Safety of Omega-3 Fatty Acids(Omacor®) for the Treatment of Immunoglobulin A Nephropathy NCT00549692 | Kuhnil Pharmaceutical Co., Ltd. | Phase 3 |
| Completed | Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy (IgAN) NCT00657059 | Sun Yat-sen University | Phase 3 |
| Completed | A Controlled Study of Uric Acid on the Progression of IgA Nephropathy NCT00793585 | Sun Yat-sen University | N/A |
| Completed | A Study of the Antioxidant Probucol Combined With Valsartan in Patients With IgA Nephropathy NCT00426348 | Guangdong Provincial People's Hospital | Phase 4 |
| Completed | Calcitriol in the Treatment of Immunoglobulin A (IgA) Nephropathy NCT00319761 | Chinese University of Hong Kong | Phase 4 |
| Completed | Sirolimus Therapy for Poor Prognosis Immunoglobulin A Nephropathy NCT00396721 | Josep m Cruzado | Phase 2 |
| Completed | Oral Treatment With PL-56 in Patients With IgA Nephropathy - an Explorative Study NCT00767221 | Calliditas Therapeutics AB | Phase 2 |
| Completed | Mycophenolate Mofetil Versus Intravenous Cyclophosphamide Pulses in the Treatment of Crescentic IgA Nephropath NCT00301600 | Nanjing University School of Medicine | N/A |
| Completed | Mycophenolate Mofetil for IgA Nephropathy NCT00863252 | The University of Hong Kong | Phase 4 |
| Terminated | Mycophenolate Mofetil (MMF) in Patients With IgA Nephropathy NCT00318474 | St. Joseph's Hospital and Medical Center, Phoenix | Phase 3 |
| Completed | Steroids and Azathioprine in Advanced IgAN NCT01392833 | A. Manzoni Hospital | Phase 3 |
| Completed | "Steroids and Azathioprine Versus Steroids Alone in IgAN" NCT00755859 | A. Manzoni Hospital | Phase 4 |
| Completed | Inhibition of the Renin Angiotensin System Plus Corticosteroids for the Treatment of Proteinuria in IGA Nephro NCT00367562 | Hospital Britanico | Phase 4 |
| Available | Managed Access Programs for EXV811, Atrasentan NCT07319585 | Novartis Pharmaceuticals | — |